Storm clouds hung over the pharmaceutical sector through 2000, in the form of election-year rhetoric about rocketing drug costs. Some companies feared the federal government might pass draconian new laws aimed at slashing drug prices. But an election that yielded an evenly split Congress and a Republican White House put an end to such talk. Meanwhile, pharmaceutical revenues were buoyed by a slew of fast-growing products that helped worldwide sales grow a healthy 11.7%, according to research firm IMS Health Inc.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.